Initiation of aripiprazole once-monthly using a two-injection start in adult patients diagnosed with schizophrenia: real-world views and experiences of Italian healthcare professionals
Rivista di Psichiatria · 2026
DOI: 10.1708/4785.48115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rivista di Psichiatria, 2026. Verfasst von Murat Yildirim und 7 weiteren Autor:innen. Beteiligte Einrichtung: H. Lundbeck A/S, Valby, Denmark. Hauptthemen laut MEDLINE: Aripiprazole, Schizophrenia, Antipsychotic Agents, Attitude of Health Personnel.
Abstract (Originalsprache)
Aim
In Italy, aripiprazole once-monthly 400 mg (AOM 400) can be initiated using a two-injection start (TIS) in adult patients diagnosed with schizophrenia who are stabilised with oral aripiprazole. With this approach, treatment initiation is completed in a single day, without the need for 14 days of concurrent oral aripiprazole supplementation. This study examined how healthcare professionals (HCPs) view and use the AOM 400-TIS in real-world clinical practice in Italy, a country where uptake of the AOM 400-TIS has been relatively high.
Methods
Responses were analysed for Italian physicians and nurses who participated in a pan-European, non-interventional, cross-sectional online survey that explored perspectives and attitudes towards prescribing and/or administering AOM 400-TIS in patients diagnosed with schizophrenia. Responses were collected across two waves and were analysed descriptively.
Results
Responses were available for 108 Italian HCPs, representing 47.2% of all survey participants. Common reasons for using the AOM 400-TIS were poor treatment adherence (81.5%), patient preference (50.0%), and disease relapse (42.6%), while common barriers to its use were patient reluctance to receive two injections (36.1%), concerns about tolerability (24.1%), and concerns about safety (23.1%). Most HCPs agreed or strongly agreed that the AOM 400-TIS resulted in satisfactory patient outcomes (85.2%), was easy to administer (82.4%), and had a safety/tolerability profile similar to the traditional one-injection start (69.4%).
Discussion
The results confirm the favourable clinical opinions, perspectives, and experiences of Italian HCPs who prescribe and/or administer the AOM 400-TIS in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- H. Lundbeck A/S, Valby, Denmark.
- Otsuka Pharmaceutical Europe, Berkshire, UK.
- Division of Psychiatry, Department of Brain Sciences, Imperial College London, UK.
- Vivantes Hospital am Urban and Vivantes Hospital im Friedrichshain, Charite, Universitätsmedizin, Berlin, Germany - Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany.
- Real-World Evidence, OPEN Health, London, UK.
- Department of Mulecolar and Developmetal Medicine, Università di Siena, Italy.
Zitieren
APA
Yildirim, M., Beckham, C., Pappa, S., Leopold, K., Cottam, W. J., Hickey, J., Rogerson, O., & Fagiolini, A. (2026). Initiation of aripiprazole once-monthly using a two-injection start in adult patients diagnosed with schizophrenia: real-world views and experiences of Italian healthcare professionals. Rivista di Psichiatria. https://doi.org/10.1708/4785.48115
Vancouver
Yildirim M, Beckham C, Pappa S, Leopold K, Cottam WJ, Hickey J, et al. Initiation of aripiprazole once-monthly using a two-injection start in adult patients diagnosed with schizophrenia: real-world views and experiences of Italian healthcare professionals. Rivista di Psichiatria. 2026. doi:10.1708/4785.48115
BibTeX
@article{Yildirim2026,
author = {Yildirim, Murat and Beckham, Clodagh and Pappa, Sofia and Leopold, Karolina and Cottam, William J and Hickey, Joe and Rogerson, Olivia and Fagiolini, Andrea},
title = {Initiation of aripiprazole once-monthly using a two-injection start in adult patients diagnosed with schizophrenia: real-world views and experiences of Italian healthcare professionals},
journal = {Rivista di Psichiatria},
year = {2026},
doi = {10.1708/4785.48115}
}
EUVIMED